Randomized, Open-label, Multi-centered Study to Evaluate the Safety and Efficacy of Pitavastatin in Patients With Impaired Fasting Glucose and Hyperlipidemia(Phase 4)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 10 May 2017
At a glance
- Drugs Pitavastatin (Primary)
- Indications Hyperlipidaemia; Prediabetic-state
- Focus Therapeutic Use
- Acronyms SIPHON
- Sponsors JW Pharmaceutical
- 08 Mar 2017 Planned End Date changed from 1 Aug 2015 to 1 Oct 2017.
- 08 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 19 Feb 2014 New trial record